Brainsway Ltd. announced that it has obtained US Food and Drug Administration (FDA) clearance for use of its Deep TMS (transcranial magnetic stimulation) device for the treatment of depression in patients who fail to respond to therapeutics during a depression episode. The company adds that the FDA approval for this indication is generally broader than the definition given by the company's TMS device rival.
BrainsWay Ltd. TEL AVIV STOCK EXCHANGE
Equities
BWAY
IL0011007189
Advanced Medical Equipment & Technology
1st Jan change | Capi. | |
---|---|---|
+4.87% | 212B | |
+9.67% | 187B | |
+28.85% | 155B | |
+35.01% | 115B | |
+2.40% | 65.5B | |
+15.37% | 52.87B | |
-6.47% | 45.25B | |
-2.78% | 39.7B | |
+7.22% | 37.72B |